DANC opening downtown office to help soldiers transition out of Fort Drum
The Development Authority of the North Country has secured a $3.9 million state grant to open the "Next Move NY" office at 124 Franklin St. in Jefferson Community College's $3-million education and entrepreneurial center, called The NEST.
The program also aims to help local businesses recruit and hire transitioning soldiers, their spouses and veterans so they can stay and work in the north country, said Michelle Capone, DANC's director of regional development.
"This is big," she said.
The collaboration with the college's entrepreneurial, education and workforce development's efforts seems to make the Next Move NY office "well-placed for that location," Capone said.
It's the first time that the transitioning soldier efforts will be located in the community. That work is done on-post at Fort Drum through its Transition Assistance Program.
The Next Move NY program will be staffed by program administrator Ben Cruz, program manager Eric Lo and a business liaison still to be hired. Cruz and Lo are former Fort Drum soldiers who will also work at Fort Drum's TAP program, besides being housed at the JCC Franklin Street site.
The downtown office is expected to open in mid-April. Some technical equipment, a logo and website still need to be developed, Capone said.
JCC's Small Business Development Center also has offices in the Franklin Street building and space for local startup businesses.
The DANC program will incorporate a job matching portal and help businesses with soldier recruitment and training for employers.
"We're looking at rolling more in the next few months," Capone said.
Kylee McGrath, CEO of the Watertown Local Development Corp., heard about the program for the first time on Wednesday morning at a breakfast of the Fort Drum Chapter of AUSA. She previously worked at Fort Drum's TAP program, so she realizes that a lot of soldiers want to stay in the area after leaving the military.
"I think it's great to keep them here," she said. "It'll be good for the local economy."
The state funding is coming through Empire State Development.
The Franklin Street office is part of a $10 million Next Move NY initiative to enhance workforce opportunities for transitioning soldiers and their families, Capone said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
3 days ago
- Forbes
This Stock Has A 3.74% Yield And Sells For Less Than Book
Molson Coors Beverage has been named as a Top 25 dividend stock, according the most recent Dividend Channel ''DividendRank'' report. The report noted that among the coverage universe, TAP shares displayed both attractive valuation metrics and strong profitability metrics. The report also cited the strong quarterly dividend history at Molson Coors Beverage , and favorable long-term multi-year growth rates in key fundamental data points. The Top 25 DividendRank'ed Stocks » The report stated, ''Dividend investors approaching investing from a value standpoint are generally most interested in researching the strongest most profitable companies, that also happen to be trading at an attractive valuation. That's what we aim to find using our proprietary DividendRank formula, which ranks the coverage universe based upon our various criteria for both profitability and valuation, to generate a list of the top most 'interesting' stocks, meant for investors as a source of ideas that merit further research.'' The annualized dividend paid by Molson Coors Beverage is $1.88/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 09/05/2025. Below is a long-term dividend history chart for TAP, which the report stressed as being of key importance. Indeed, studying a company's past dividend history can be of good help in judging whether the most recent dividend is likely to continue.
Business Wire
4 days ago
- Business Wire
BiVACOR Total Artificial Heart Accepted into FDA's Total Product Life Cycle (TAP) Program
HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)--BiVACOR, Inc., a clinical-stage medical device company developing the world's first titanium Total Artificial Heart (TAH), today announced that its TAH System has been accepted into the U.S. Food and Drug Administration's (FDA) prestigious Total Product Life Cycle (TPLC) Advisory Program, also known as the TAP program. This milestone further solidifies BiVACOR's collaboration with the FDA following the TAH's earlier recognition this year as a Breakthrough Device. This isn't just a vote of confidence in BiVACOR, it's a vote of confidence in the future of heart replacement technology. The TAP program gives us the opportunity to collaborate with the FDA at a level that aligns with urgency and magnitude of our mission. Share The TAP program is a transformative FDA initiative designed to accelerate the development and patient access to high-impact medical technologies. Entry into the program provides BiVACOR with proactive, strategic engagement with the FDA throughout the entire product life cycle, from development to commercialization, supporting more efficient, risk-informed decision-making. TAP participation is reserved for breakthrough-designated devices with the potential to significantly improve patient outcomes for serious or life-threatening conditions. 'Acceptance into the TAP program marks a major milestone not just for BiVACOR, but for the field of mechanical circulatory support as a whole,' said Daniel Timms, Founder and Chief Technology Officer of BiVACOR. 'The BiVACOR TAH has the potential to fundamentally redefine the standard of care for patients with end-stage heart failure. TAP access gives us a powerful framework for working hand-in-hand with the FDA to bring this technology to the patients who need it most.' The BiVACOR TAH is intended for use as a bridge to transplant in adults with severe, irreversible biventricular or univentricular heart failure, particularly for patients who cannot be treated with traditional left ventricular assist devices (LVADs). The system employs a magnetically levitated centrifugal pump, inspired by space and industrial technologies, which provides continuous, pulsatile, and physiologically responsive cardiac support. The FDA's acceptance letter to BiVACOR emphasized that the TAP program's inclusion reflects the agency's confidence in the technology's potential to transform clinical practice. As part of the program, BiVACOR will receive more regulatory guidance, earlier identification of scientific and evidentiary gaps, and greater coordination among stakeholders, including payers and patient advocacy groups. 'This isn't just a vote of confidence in BiVACOR, it's a vote of confidence in the future of heart replacement technology,' said William Cohn, MD, BiVACOR Chief Medical Officer and renowned cardiac surgeon. 'The TAP program gives us the opportunity to collaborate with the FDA at a level that aligns with the urgency and magnitude of our mission to bring a durable, fully implantable artificial heart to patients with no other options.' The TAP program was established as part of the FDA's efforts to modernize device development oversight and ensure the U.S. remains at the forefront of medical innovation. The program currently operates as a pilot under the Center for Devices and Radiological Health (CDRH), with acceptance based on strict criteria outlined in the Federal Register (87 FR 61605). BiVACOR's participation in TAP follows several recent milestones for the company, including its first-in-human implant as a bridge to support a patient awaiting a cardiac transplant. The company is now progressing toward expanded clinical trials in the U.S. and internationally. For more information on the FDA's TAP program, visit: Participation in the FDA's Total Product Life Cycle Advisory Program (TAP) does not imply FDA approval, clearance, or authorization. Inclusion in the TAP Pilot does not guarantee future marketing authorization or a regulatory outcome. The BiVACOR TAH is currently used as an investigational device and is not approved for commercial use. About BiVACOR BiVACOR ® is a clinical-stage medical device company developing a fully implantable, magnetically levitated Total Artificial Heart for long-term support of patients with end-stage biventricular heart failure. Founded by biomedical engineer Daniel Timms, PhD, and backed by leading experts in cardiovascular medicine including Dr. William E. Cohn and Dr. O.H. (Bud) Frazier, the company is conducting an FDA-approved Early Feasibility Study in the U.S. Headquartered in Huntington Beach, CA, with clinical operations in Houston and engineering offices in Gold Coast, Australia, BiVACOR is committed to addressing the global shortage of donor hearts through advanced, scalable technology. Learn more at
Business Insider
5 days ago
- Business Insider
Aluminum Tariffs Weigh on Canadian Beer Maker Molson Coors (TAP)
The stock of Molson Coors (TAP) is down after the Canadian beer maker warned that aluminum tariffs are likely to hurt its profits this year. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The company, which is co-headquartered in Montreal and Chicago, forecast a bigger drop in its annual profit due to tariff impacts on the cost of its aluminum beer cans. Management also cited macroeconomic uncertainty in the U.S. as a reason for its gloomy outlook. The company, which produces most of its beer at U.S.-based breweries in Colorado, nevertheless faces a 50% tariff on aluminum metal that's shipped into the U.S. In June of this year, U.S. President Donald Trump doubled the aluminum tariff from 25% previously. Alcohol Spending Molson Coors says that President Trump's fluctuating tariff policies have pressured consumer spending and led people to pare back their discretionary spending on items such as alcohol. As a result, the company expects its annual earnings to decline 7% to 10% compared to its prior forecast of a low single-digit increase. For this year's second quarter, Molson Coors reported that its net sales fell 1.6% to $3.2 billion, but came in ahead of analyst estimates of $3.1 billion. The company posted Q2 earnings per share (EPS) of $2.05, beating consensus estimates of $1.83. TAP stock has fallen 13% this year. Is TAP Stock a Buy? The stock of Molson Coors has a consensus Moderate Buy rating among 16 Wall Street analysts. That rating is based on six Buy and 10 Hold recommendations issued in the last three months. The average TAP price target of $59.73 implies 23.90% upside from current levels. These ratings are likely to change after the company's financial results.
